{"name":"Ono Pharmaceutical Co. Ltd","slug":"ono-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"ono.com","description":"","hq":"Chūō-ku","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"ONO-4059","genericName":"ONO-4059","slug":"ono-4059","indication":"Relapsed or refractory lymphoma","status":"phase_3"},{"name":"Adlumiz","genericName":"ANAMORELIN","slug":"anamorelin","indication":"Cancer cachexia","status":"marketed"},{"name":"Docetaxel/Paclitaxel","genericName":"Docetaxel/Paclitaxel","slug":"docetaxel-paclitaxel","indication":"Metastatic or locally advanced non-small cell lung cancer","status":"phase_3"},{"name":"Minodronic acid hydrate","genericName":"Minodronic acid hydrate","slug":"minodronic-acid-hydrate","indication":"Osteoporosis in postmenopausal women","status":"phase_3"},{"name":"ONO-1101","genericName":"ONO-1101","slug":"ono-1101","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"ONO-4538","genericName":"ONO-4538","slug":"ono-4538","indication":"Non-small cell lung cancer","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"ONO-5920","genericName":"ONO-5920","slug":"ono-5920","indication":"Pulmonary arterial hypertension","status":"phase_3"},{"name":"FOY-305","genericName":"FOY-305","slug":"foy-305","indication":"Thrombotic disorders (investigational)","status":"phase_3"},{"name":"ONO-8025 (KRP-197)","genericName":"ONO-8025 (KRP-197)","slug":"ono-8025-krp-197","indication":"Pulmonary arterial hypertension","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Sivelestat sodium hydrate","genericName":"Sivelestat sodium hydrate","slug":"sivelestat-sodium-hydrate","indication":"Other","status":"marketed"},{"name":"ONO-7475","genericName":"ONO-7475","slug":"ono-7475","indication":"Other","status":"phase_1"},{"name":"imidafenacin, KRP-197/ONO-8025","genericName":"imidafenacin, KRP-197/ONO-8025","slug":"imidafenacin-krp-197-ono-8025","indication":"Overactive bladder (urge urinary incontinence)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"MK-0431/ONO-5435","genericName":"MK-0431/ONO-5435","slug":"mk-0431-ono-5435","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Placebo, MK-0431/ONO-5435","genericName":"Placebo, MK-0431/ONO-5435","slug":"placebo-mk-0431-ono-5435","indication":"Type 2 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"ONO-4059","genericName":"ONO-4059","slug":"ono-4059","phase":"phase_3","mechanism":"ONO-4059 is a small-molecule inhibitor of phosphoinositide 3-kinase (PI3K) that blocks PI3K signaling to suppress tumor cell proliferation and survival.","indications":["Relapsed or refractory lymphoma","Other hematologic malignancies"],"catalyst":""},{"name":"ONO-5920","genericName":"ONO-5920","slug":"ono-5920","phase":"phase_3","mechanism":"ONO-5920 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation.","indications":["Pulmonary arterial hypertension","Chronic thromboembolic pulmonary hypertension"],"catalyst":""},{"name":"Sivelestat sodium hydrate","genericName":"Sivelestat sodium hydrate","slug":"sivelestat-sodium-hydrate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adlumiz","genericName":"ANAMORELIN","slug":"anamorelin","phase":"marketed","mechanism":"Growth hormone secretagogue receptor type 1","indications":["Cancer cachexia"],"catalyst":""},{"name":"Docetaxel/Paclitaxel","genericName":"Docetaxel/Paclitaxel","slug":"docetaxel-paclitaxel","phase":"phase_3","mechanism":"Docetaxel and paclitaxel are taxane chemotherapy agents that stabilize microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis.","indications":["Metastatic or locally advanced non-small cell lung cancer","Metastatic breast cancer","Gastric adenocarcinoma","Head and neck cancer"],"catalyst":""},{"name":"FOY-305","genericName":"FOY-305","slug":"foy-305","phase":"phase_3","mechanism":"FOY-305 is a Factor IIa (thrombin) inhibitor that blocks the coagulation cascade to prevent thrombotic events.","indications":["Thrombotic disorders (investigational)"],"catalyst":""},{"name":"MK-0431/ONO-5435","genericName":"MK-0431/ONO-5435","slug":"mk-0431-ono-5435","phase":"phase_3","mechanism":"MK-0431/ONO-5435 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Minodronic acid hydrate","genericName":"Minodronic acid hydrate","slug":"minodronic-acid-hydrate","phase":"phase_3","mechanism":"Minodronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","indications":["Osteoporosis in postmenopausal women","Bone loss associated with cancer treatment"],"catalyst":""},{"name":"ONO-1101","genericName":"ONO-1101","slug":"ono-1101","phase":"phase_3","mechanism":"ONO-1101 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"ONO-4538","genericName":"ONO-4538","slug":"ono-4538","phase":"phase_3","mechanism":"ONO-4538 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Melanoma"],"catalyst":""},{"name":"ONO-7475","genericName":"ONO-7475","slug":"ono-7475","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ONO-8025 (KRP-197)","genericName":"ONO-8025 (KRP-197)","slug":"ono-8025-krp-197","phase":"phase_3","mechanism":"ONO-8025 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation.","indications":["Pulmonary arterial hypertension","Chronic thromboembolic pulmonary hypertension"],"catalyst":""},{"name":"Placebo, MK-0431/ONO-5435","genericName":"Placebo, MK-0431/ONO-5435","slug":"placebo-mk-0431-ono-5435","phase":"phase_3","mechanism":"MK-0431/ONO-5435 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"imidafenacin, KRP-197/ONO-8025","genericName":"imidafenacin, KRP-197/ONO-8025","slug":"imidafenacin-krp-197-ono-8025","phase":"phase_3","mechanism":"Imidafenacin is an antimuscarinic agent that acts as a selective M3 receptor antagonist.","indications":["Overactive bladder (urge urinary incontinence)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQbFhyQ0FXRHJjYkg2aG1KNS1ocHg0ZWRQRWxfWU44ajZpSXg3YS1aM2oycFM5SURaSzZOd1k3QW5HUmN2bktFX0JrVEg1ZVkyX1BGdGpGUTZPcGNLcC13TXduWkUzTDczdEc5ejBJckQza2h1dFdtYlVMYXdPN0s1TnFJR2NuZExuYmo0bExSNUMzczBuOGdpc3RVRnVxNFlYX2EyYjljaURudURnU0xzYWQyTFBJNVhLbGFTLTM3d3hOZDYyanlXMXd0UUtCVzNDS1NrcTZIYXplU3VZQVg0eElyQlhWY1BRanpMTVNDblo5em1ocUJfSDBZRnJFZV9RV2ktY3hvaG9sb1lZSERKUGcwYUc2RFNnTEluQw?oc=5","date":"2026-03-26","type":"regulatory","source":"Business Wire","summary":"Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan - Business Wire","headline":"Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Strom","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQY19HcWc3Z3BES3NYVndSZ2luREpub04zdGRXZnJIa1JKYmdyM2dGQjdWTTREeTBwNGNJQmh5YTZjOGJPTnByaVdUY2hXbXZydnZSSkRUUkF3YlRxUEJubTBSaUZZbmhvdEZzUDNvZWgxNVlXY0VsYkJJNW0tSkFwZm9mQzdvSjdrUUMwcVlHSDdKVmVrMmxnc2dodjVvM2FQb0tDMUZlQ3VwdC15UWJua21yUm13dmFwOWhYMEdIN3o5WEdxQ3JfV1ZNRjh5OWZEbmlwUk91dUYzOGJKUFN2Vmhhc2FaT2VsOW1aQUtraEUydw?oc=5","date":"2026-03-02","type":"deal","source":"PR Newswire","summary":"Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs - PR Newswire","headline":"Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxPaWo5SkxiVXJiVWxJR3ZGUTBpUW5TczNEOW5vclZXZzlYbHJVcF85UWpNZHhxUVlsNi1XeGplM2hTSlpGVUxMbDdJOFNTQ1NLQ0ZLSzYxcG0xUzdKcV9UblA5dVY1Vng0cEZJakhDN0Z3cmVDZWxxNUtNSGpzYXhnT2VIWGZzcUg4Y3BEM1FOZHZ0dEw4WWhyOC1EU0FsNnAxUTNkS3NOZFVheExxNEZyNFZSRFY5M0tNU01PdHd2OVUxUmItMVJJOGlqeHUwVFVVUFgzRVktMUxESmcxMFJKSjRSM244WDBTb1FiZ18zN0FValN4SGhrUTQxSEY4bFJNa2UzNV9PMnFpUThVZU9kZzRFV3FfV3Uw?oc=5","date":"2026-03-02","type":"deal","source":"Business Wire","summary":"Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology - Business Wire","headline":"Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOU3Z5M1ZNMGw4ak9BMVJ5YnhVQjZ2Y1dNV3hzWFA4SGVwenA2OEk5SGI2NkpfbnNBTWcxd3I3d1A1MmNkZjI4MEJ1dnlydFhKTDZGTkgtSC0tZ3EyWWFaOUxDckotRnp2N3c5WjNESWhRMkdkc0VGbFhBZE1ENk9ZbkJxRUdMUTdubHhwOEtiLXpLOXpxXzkxUVhIekg4eU1rTVpOc0Z5U2NIMl9maGJ3LW1Sc2NFZnZzTUNxVHJHckFaQQ?oc=5","date":"2026-02-13","type":"pipeline","source":"Monash University","summary":"Monash University and Ono Pharmaceutical sign two licence agreements - Monash University","headline":"Monash University and Ono Pharmaceutical sign two licence agreements","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-05","type":"earnings","source":"simplywall.st","summary":"Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st","headline":"Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxORHYzVTVnQzhLcDZrSThLVU0yRHJBb2t0YTdZWEJmTjR3a0Ixd0JJUlk4SXJxSlBiUndlb2lhVlpkdURTclF0VF8xXzJCeXd0UE5Sb3lFVm1abzFxRFk5TmpQQzBtXzFrX2dYMS1OaVZabTdTVHJPOHBQcUl4WDNodUZydXduVHhXTWVrYWpSdWJJUnNxNDJMUDRadDVocnFncFFwR0F0MDN4TUw1MnlBTUZQU0NmQl9SMWpSUHVUaXJ5Nkk?oc=5","date":"2025-12-10","type":"pipeline","source":"Vanderbilt University","summary":"Limited Submission Opportunity: 2026 Ono Pharma Breakthrough Science Initiative Awards - Vanderbilt University","headline":"Limited Submission Opportunity: 2026 Ono Pharma Breakthrough Science Initiative Awards","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPYzVfWnZ0RFBTRWJ1Ty1YQ2FCeWxQb1ZVUzNUNlZRamRZTHBRb052SzhfUjF4dUpmWm9iMU83d25ERmVyQmxNdkVhb0pfQURwQ2xvUnQwNDZ6NGk5ZFVsdU1DR3BKcnNrNC1ydzl5aFZRRWNNZHBiZDVaM01wblppUHU3RW9TRXlSd3hWblVldkVaN0xOdVV3?oc=5","date":"2025-11-17","type":"pipeline","source":"Contract Pharma","summary":"Ono Pharma Opens New Office in Zug, Switzerland - Contract Pharma","headline":"Ono Pharma Opens New Office in Zug, Switzerland","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxPcTN4YnA4anZYN29JakdMVkk0LVdGakY5Z0twVUtXQUEtVG9tZkNvVFhBN3dCVDdjMDBXTlEybkpNY3RaSHRPckxMQURGWEFvcWhFNldUTTd5SExLMFpTWGpfcXNaSG9vN0hqaHp6QTV2bUNqMWY2bHRzTk9XWDl0a09VcXh5cTh6Sk5JNkFSbFY0dXBqRDdHeUpQMkJRQjR3SVN0c3RfV2dhbnR0ZlJvVVNidExsNDhRd1JRazRYTXp3MTBrOFBFWjJZTlFlR3FNTDlsU0VaSXJ5ZkR4OXJuTFlMSWo3cUhKQklMZ05jblNqZTZhbEVoTVVsUk5WR3lZRk9kNGNKc29UZ1lEOGpONXJBck40WEhlV0FkWTJ3?oc=5","date":"2025-11-14","type":"deal","source":"PR Newswire","summary":"PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. - PR Newswire","headline":"PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Phar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOREJMUzJNV3FPWk1BTHItTGZxSnhfd2dWbWcwcmozcG5nUG9qRmdGVVAxSk1EbUJDQkF2YV9jX191VXBZMkJuUjZvMm14b2VWM2RLS2tuT2V2Ry1sT05jbnd3WGdBTWlUWTNwWE5keElUN0JEY09QMnZZY1N5RFNaNnBZVVBQcnBVSVNucElZUlo5amJQNDBRSXJSeXA5Sk9xZkNNdDBCTGh6ckxOMm9zOHFyZWdndlFfVmh4SEl6ZUtxUjVIbUE?oc=5","date":"2025-10-12","type":"trial","source":"BioPharma APAC","summary":"Ono Pharma Reports Positive Phase 2 Signals for ONO-2808 in Multiple System Atrophy - BioPharma APAC","headline":"Ono Pharma Reports Positive Phase 2 Signals for ONO-2808 in Multiple System Atrophy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE00LWEzX2tVSlRKQVR2eWJDdDdlX1BpVnhGUVZzN1NmT0QwZHpLNW9KWW9pdmlNZ08zSnBuVUFZMk1BRkx2R1gydFJFZVlja1llcHpkNy00Q3lhcmlfbG9aQzE2TWhlWGQ3YWJ4WQ?oc=5","date":"2025-10-02","type":"pipeline","source":"ono-pharma.com","summary":"Message from the CEO | Corporate Reports | IR Library | Investors | ONO PHARMACEUTICAL CO., LTD. - ono-pharma.com","headline":"Message from the CEO | Corporate Reports | IR Library | Investors | ONO PHARMACEUTICAL CO., LTD. - ono","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5RRnVhMVdXaExVbk0zNzFtZnNWalVjYm0wb3FKbFRqQXdKTmN3OXVoMUh2VnRPeEMzR2dnOXdWY3hENmNSbldNX1NXbGItVVNTOVBhdWtKRWFUSVdRRDZWenJMeU5oV19Ca3dyMA?oc=5","date":"2025-10-01","type":"pipeline","source":"ono-pharma.com","summary":"Message from the COO | Corporate Reports | IR Library | Investors | ONO PHARMACEUTICAL CO., LTD. - ono-pharma.com","headline":"Message from the COO | Corporate Reports | IR Library | Investors | ONO PHARMACEUTICAL CO., LTD. - ono","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOczhtX2FiUGJrU010N2VkVnpzQ2x2NV85eFdYenAtUVpOSmsyUV9zekNEOU53dUJ0VzB5UE1YSU9fMVVxanY1UEtSd3RMQ2dQTUo1MGdPVzJYel9NOHFKa0VtR0ExT2ZIUW9OUkVNSWlNa3g5OFpFbkR5a0poUVdmaUFTOEp4dmpCRmd6NXVTU3c0MG5E?oc=5","date":"2025-06-23","type":"pipeline","source":"Yahoo Finance","summary":"Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea - Yahoo Finance","headline":"Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South ","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"phase_3":11,"marketed":2,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}